appeals for gip glp 1 Indications GLP-1/GIP RA Summary Sheet and Beyond! GLP1-GIP receptor co-agonists: a promising

A., Jensen, T., Sanchez-Lozada, L

62 Another study that evaluated clinical outcomes in patients with diabetes, treated by cardiac resynchronization therapy with a defibrillator (CRT-d), and glucagon-like peptide 1 receptor agonists (GLP-1 RA) in addition to conventional hypoglycemic therapy versus CRTd patients under conventional hypoglycemic drugs found that CRTd patients with diabetes treated by GLP-1 RA therapy versus CRTd patients with diabetes that did not receive GLP-1 RA therapy, experienced a significant reduction of NYHA class, associated to higher values of 6 minutes walking, and higher rate of CRTd responders

Early preclinical and small-scale human studies suggest these drugs may influence brain reward pathways involved in addictive behaviours, potentially reducing alcohol cravings and intake

Retatrutide on the plotter: the triple agonist difference Retatrutide adds a fascinating new dimension to GLP-1 plotting because it activates three receptors rather than one or two

OBrien PE, Hindle A, Brennan L, Skinner S, Burton P, Smith A, et al

[DOI] [PMC free article] [PubMed] [Google Scholar] 55